Novo Nordisk invests 500 million Danish kroner in expanding tablet production in Denmark

25 February 2021

Danish diabetes care giant Novo Nordisk (NOV: N) today announced plans to invest 500 million Danish kroner ($81.6 million) in expanding facilities at its production site in Måløv, Denmark.

The facility currently manufactures products for oral diabetes treatment and will be expanded to ensure capacity for future production of these products. The project is expected to be completed in 2022, the company noted.

“This investment in our production facilities in Måløv is an important step in building and ensuring future capacity for production of Rybelsus (oral semaglutide). Måløv is currently our cornerstone in the production of oral semaglutide, and it is critical that we invest timely in capacity expansion to meet the future demands,” said Henrik Steen Jensen, corporate vice president for Novo Nordisk oral semaglutide production.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK